NanoViricides, Inc. (NYSE American: NNVC) announced that Proactive Investors published an analyst research report detailing the Company’s dual-track clinical development strategy for NV-387, its broad-spectrum antiviral drug candidate targeting both MPox and respiratory viral infections, including influenza, coronaviruses, and RSV. The report notes NV-387’s nano-polymer micelle technology, which binds and neutralizes virus particles before they infect cells.
Following completion of a Phase 1 safety and tolerability study in 2023, NanoViricides plans to initiate a Phase 2 trial for MPox in Congo by late 2025 or early 2026, with ethics approval already secured. The report also highlights potential U.S. biodefense funding opportunities through BARDA based on successful trial outcomes. To view the full press release, visit https://ibn.fm/ib5Cg.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate is NV-387, which the company plans to develop as a treatment for RSV, COVID, long COVID, influenza and other respiratory viral infections, as well as MPOX/smallpox infections. Another advanced drug candidate is NV-HHV-1 for the treatment of shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The company also has drug candidates NV-CoV-2 (API NV-387) for COVID-19 that does not encapsulate remdesivir, and NV-CoV-2-R which encapsulates remdesivir. NanoViricides believes that since remdesivir is already FDA approved, its drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. Additionally, the company is developing drugs against a number of viral diseases including oral and genital herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever and Ebola virus.
NanoViricides’ platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of human viral diseases such as HIV/AIDS, hepatitis B virus, hepatitis C virus, rabies, herpes simplex virus, varicella-zoster virus, influenza and Asian bird flu virus, dengue viruses, Japanese encephalitis virus, West Nile virus, Ebola/Marburg viruses and certain coronaviruses. The company intends to obtain a license for RSV, poxviruses and/or enteroviruses if initial research is successful.
As is customary, NanoViricides notes the risk that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts, there can be no assurance at this time that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in the lab will lead to successful clinical trials or a successful pharmaceutical product. For the latest news and updates relating to NNVC, visit the company’s newsroom at https://ibn.fm/NNVC.
